Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sterling Drug

Executive Summary

Obtains an exclusive worldwide license from Xoma to the chimeric pan-carcinoma monoclonal antibody ING-1, which is currently in preclinical evaluation for a number of types of cancer. Xoma will receive a technology access fee and royalties from future product sales. Sterling, which will conduct all further development work on ING-1, will also receive a nonexclusive license to certain Xoma genetic engineering technologies for cancer applications. Xoma says the move is its first in connection with an earlier decision to license some of its cancer-related drug development programs and concentrate on products for infectious diseases and immune disorders. While Xoma's initial product development efforts have been with murine antibodies, the company's 1989 acquisition of Ingene provided chimeric monoclonal antibody technology.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS019505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel